In this editorial webinar, we bring together leading experts to discuss what major trends are occurring across the industry in the development of new methods of drug delivery, as well as improvements to existing ones. We aim to inform the listeners of...
The term “special population” exists to protect certain vulnerable patient groups that require additional consideration as it pertains to clinical research, including women, pediatrics, and the elderly.
Artificial intelligence (AI) is the industry’s latest buzzword and is being touted as the solution to myriad problems. So where will it have the biggest impact across the drug development continuum? From identifying repurposable drugs, to mining data...
Be a catalyst for change at the 2019 Bridging Collaborative where thought leaders come together to advance clinical research and health care. Establish solutions to increase knowledge-sharing from clinical research.
This event will examine the drug excipients market, from the historical events that have defined the sector to the debates going on at the moment to predictions about the demands that will drive it in the future.How did the DEG tragedies of the last century...
It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.But,...
How healthy is demand for bioavailability enhancement services? Is the growth of the generics sector driving the market or do innovative pharma firms determine the type of solubility solutions that are available.When biopharmaceutical are injected they...
Tablets have been around for almost 200 years. In this presentation we trace the history of their development, from the accidental invention of the sustained release pill through to the latest breakthroughs in bioavailability enhancement, this talk will...
How do you take a successful bioavailability solution from the laboratory to the pilot plant and on to commercial-scale production? What are the potential pitfalls and considerations involved in successfully scaling-up the production of a poorly soluble...
Creating an Amorphous Solid Dispersion (ASD) is an increasingly popular way of improving Active Pharmaceutical Ingredient (API) solubility. But while the approach can be successful, the big problem is demonstrating ASD stability, preventing ingredients...
Cancer drug development is the most complex challenge faced by the drug industry today, with clinical trials being the most technically difficult, time consuming and expensive aspect of the process. Recruiting patients, monitoring sites and...
On average over half the cost of developing a new cancer drug is associated with work outsourced to contract research organisations (CRO), according to analysis by Cutting Edge Information. This finding, coupled with the pharmaceutical industry’s ever...
Recruiting patients is often, if not always, the most expensive and time consuming part of a clinical trial. For oncology drug development the problem is particularly pronouncedThis presentation will focus on new techniques to improve access to the right...
The way drug companies work with CROs is evolving, with the emphasis shifting from the client-service provider model to a more strategic, long-term relationship focused approach.This presentation will discuss the role strategic partnerships can play in...
Recruiting patients is often, if not always, the most expensive and time consuming part of a clinical trial. For oncology drug development the problem is particularly pronounced.This presentation will focus on new techniques to improve access to the right...
